ABSTRACT-Two tumors, human sarcoma #1 (HS #1) and human epidermoid carcinoma #3 (HEp #3), were cultured on the chorioallantoic membrane of chick embryos. Under experimental conditions, HS #1 does not metastasize, whereas HEp #3 metastasizes extensively to chick embryo lungs and other organs. The glycosphingolipid profiles of these tumors were studied and HEp #3 was found to contain about 2.5-fold less lipid-bound sialic acid per 100 mg of total lipid extracted than did HS #1, due mainly to smaller levels of monosialoganglioside (3.7-fold) and disialoganglioside (3.8-fold) in HEp #3. The total amount of neutral glycosphingolipids was approximately the same in both tumors, but their profiles differed. Treatment of these tumors with 6,7,8,9-tetrahydro-1-mercapto-1 ,2,4-triazolo-[4,3-a]quinazolin-5-01 (2.5 mg/egg/tumor) completely inhibited the formation of metastases in HEp #3 and increased the total content of lipid-bound sialic acid in the tumor by 63% (hematoside, monosialoganglioside, and disialoganglioside by 71, 99, and 67%, respectively). No change was seen in the content of lipid-bound sialic acid in HS #1. Treatment of HEp #3 with a smaller dose of the quinazolinol derivative (1.25 mg/egg) caused an average of 88% inhibition of metastasis, with a 37% increase in lipid-bound sialic acid.
Formation of metastasis is a complicated phenomenon which is affected by many factors (1, 2) . Apparently, malignant cell adhesion in a primary tumor and/or adhesion of blood-borne malignant cells to distant target organ cells may be key factors that determine the formation of metastasis (3) (4) (5) (6) (7) . Several hypotheses concern the molecular interaction between cell surfaces resulting in cell adhesion [for review, see (8) ]. Recently, several investigators considered that complex carbohydrates, including glycosphingolipids, may determine, or at least participate in, cell adhesiveness (9) (10) (11) (12) (13) (14) (15) . If this is true, then one might expect that the profile and/or quantities of glycosphingolipids present on the cell surfaces of metastasizing and nonmetastasizing experimental tumors would be different. Moreover, experimental alteration of the metastatic properties of certain tumors, e.g., inhibition of metastasis formation by treating tumor-bearing animals with certain chemicals, would also be expected to result in alteration of glycosphingolipid profiles of these tumors. Presented below are experimental data obtained for 2 different tumors; these data basically confirmed the anticipated results.
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MATERIALS AND METHODS
Tumors.-HS #1 and HEp #3 were studied (16, 17) . Both tumors were cultured on the chorioallantoic membrane of chick embryos (18, 19) . HEp #3 metastasizes from its site of implantation to the chick embryo parenchyma of various organs including lung, brain, heart, and liver (20) . However, HS #1, under similar experimental conditions, does not metastasize. These tumors have been maintained at the Merck Institute for Therapeutic Research by weekly serial passage into embryonated chick eggs with no conditioning of the host by a procedure similar to that described by Harris (19) .
The procedure for measuring the effects of potential chemotherapeutic drugs on the growth of the primary implant and on its metastasis to the chick embryo lung was previously described (20) . A fragment of HEp #3 or HS #1 tumors weighing approximately 30 mg was implanted onto each of the chorioallantoic membranes of lO-day-old embryonated chick eggs. On days 1 and 2 after implantation, compounds to be tested for antimetastatic activity were suspended in 0.25 ml of vehicle solution and then injected into the chorioallantoic membrane of the chick embryo. Control embryonated chick eggs received only vehicle solution. On day 1 post implantation, 10 tumor-bearing eggs were harvested to obtain the "initial weight" of tumors. On day 8, the surviving eggs were harvested: Tumors from both treated and control groups were weighed ("final weight"). The tumor weight representing growth is the difference between the final weight and initial weight. Examination for metastasis in lungs and other organs ABBREVIATIONS USED: HEp #3=human epidermoid carcinoma #3; HS #1 =human sarcoma #1; T/C=ratio of ganglioside (or neutral glycosphingolipid) content of treated and nontreated tumors.
was performed as described elsewhere (20) . All tumors to be analyzed for their glycosphingolipid profiles after harvesting from embryonated eggs were immediately frozen in containers immersed in Dry Ice. For each experiment, tumors from 20-30 implanted eggs were combined. Samples were kept in Dry Ice-immersed containers for about 4 hours and later subjected to lipid extraction.
Compounds tested.-In most of the experiments, the effect of the antimetastatic compound 6,7,8,9-tetrahydro-I-mercapto-l ,2,4-triazolo-[4,3-a [quinazolin-Ii-ol on glycosphingolipids in HEp #3 and HS #1 was investigated.
Originally, this compound was received from Dr. Tamio Nishimura, Kitasato Institute, Tokyo, Japan. Subsequent batches of this compound were synthesized at the Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, by Dr. N. P. Jensen. The amount of quinazolinol derivative injected per egg was 2.5 mg if not otherwise indicated. This dose had some inhibitory effect on the growth of the primary tumor of HEp #3 and caused a nearly 100% inhibition of metastasis formation. Injection of the quinazolinol derivative at a dose of 1.25 mg/egg had no effect on the growth of the primary tumor of HEp #3 and caused, on the average, an 88% inhibition of metastasis formation (from 71 to 100% in different experiments). Injection of a 2.5-mg dose into eggs with implanted HS #1 also had some inhibitory effect on the growth of the primary tumor.
The effect of another compound with antimetastatic action, 2,5-diphenylthiazolo- [5,4-d] thiazole, also has been tested. This compound, at a dose level of 500 ug/egg, strongly inhibited the formation of metastasis for the HEp #3 tumor but enhanced the growth of the primary tumor.
Chromatographic glycosphingolipid standards and adsorbents. -The following glycosphingolipids were used as reference compounds throughout the study; monoglycosylceramide [phrenosin, isolated from bovine spinal cord (21) (27) with some modification to secure complete extraction of gangliosides (28) . The lipid extracts were cooled to 4-5 0 C and washed with a volume of water one-fifth that of the total extract volumes according to the procedure of Folch et a1. (27) . Only one washing was performed.
The upper phase of the Folch wash of each sample was treated as described in (28) , including dialysis against water (29) , and the purified material from the upper phase was finally dissolved in a measured volume of chloroform:methanol (1:1, vol/vol). This fraction contains most of the gangliosides extracted from tumor tissue.
The lower phase of the Folch wash was evaporated to a small volume under reduced pressure in a nitrogen atmosphere and quantitatively transferred into a volumetric flask. This fraction contained practically all the simple lipids, phospholipids, and neutral glycosphingolipids, with the possible exception of neutral glycosphincolipids containing more than 7 or 8 sugar monomers. It also contained substantial amounts of gangliosides with lower molecular weight (hematoside and monosialoganglioside). The concentration of the "total lipids" in this fraction was determined by weight. All data concerning the ganglioside content in the lower or upper phases of the Folch wash were standardized to correspond with the amount of ganglioside that would be found in 100 mg of this total lipid extract.
Determination of gangliosides in upper Folch phase.-
The purified ganglioside-containing concentrate obtained from the upper phase of the Folch wash was subjected to analytic thin-layer chromatography. The chromatoplates were activated before use for at least 1 hour at 110°C. To these the gangliosides were applied in amounts equivalent to that found in 100-150 mg of the total lipid extract. Two developing systems were used for each sample: chloroform:methanol:0.25% aqueous CaCh, 60:35:8 (vol/vol) (30) and chloroform:methanol:2.5 M aqueous NH40H, 60:45:9 (vol/vol) (31) . Both thin-layer chromatography systems gave quantitatively similar results. Spots (or bars) on the chromatograms were visualized under UV light after use of a" Primuline spray (32) , as adapted in our laboratory for glycosphingolipid detection (33) . The gangliosides on thin-layer chromatograms were identified by their mobilities in relation to reference standards. (In some instances reference gangliosides were used as internal standards.) Identified spots (bars) were scraped off, and the gangliosides were eluted from the silica gel. Four elutions were performed. The first two elutions were performed with chloroform: methanol, 1:1 (vol/vol), to which a 5% volume of water was added. The third and fourth elutions were performed with chloroform:methanol, 1:2 (vol/vol), to which a 5% volume of water was added. All eluates were combined, and the sialic acid content was determined with resorcinol reagent according to Miettinen and Takki-Luukkainen (34) .
Determination of gangliosides in lower Folch phase.-
To analyze the content of hematoside and monosialoganglioside in the lower Folch phase, they first had to be separated from the other lipids in this fraction. Two procedures were used for this purpose. When neutral glycosphingolipids were analyzed, the above-mentioned gangliosides were separated and purified with the neutral glycosphingolipids. (See "Determination of neutral glycosphingolipids.") However, when only the amount of gangliosides in the lower Folch phase needed to be determined, a simpler procedure was applied, as described by Skipski et al. (28) . According to this procedure, 40-50 mg of total lipid obtained from the lower Folch phase were chromatographed on a small dry silicic acid column followed by thin-layer chromatography. The separated ganglioside spots were scraped off, and gangliosides were .eluted and quantitated as described above for the upper Folch phase. The total amount of hematoside and monosialoganglioside in tumors HEp #3 and HS #1 is the sum of their respective amounts in the upper and lower Folch phases.
Determination of neutral glycosphingolipids.-Common neutral glycosphingolipids are almost all present in the lower Folch phase. A short description of this procedure (old version) has been published in a review article on neutral glycosphingolipid analysis (33) . From the lower Folch phase, 80-100 mg total lipid was applied at 4°C in, at most, 2 ml of chloroform:methanol, 2:1 (vol/vol), to a 20-g silicic acid-Florisil (1:1, wt/wt) column packed in chloroform. The ratio of height to diameter of adsorbent in the packed column was 12:1. The column was eluted with 500 ml of chloroform, and this fraction was discarded. (It contained only simple lipids.) The elution was continued with pyridine (freshly redistilled):acetone:water, 6:4: I (vol/vol). Two subfractions were collected: A-subfraction (145 ml) and B-subfraction (150 ml). These subfractions were treated similarly but separately. This elution scheme was necessary to maximize recovery of the higher molecular weight neutral glycosphingolipids (such as pentaglycosylceramide) and to minimize the contamination of lower molecular weight glycosphingolipids by phospholipids. Both A-and Bsubfractions were evaporated to small volumes and subjected to preparative thin-layer chromatography. Chromatograms were developed with chloroform:methanol:acetone:water, 65:30:2:3 (vollvol) halfway up the chromatoplate. The chromatograms were then dried in a vacuum oven at room temperature for at least 30 minutes. The chromatograms were then developed to the full height of the plate in a second developing solution of chloroform:methanol:acetone:water, 65:20:2: I (vollvol). The chromatograms were allowed to air dry for at least 15 minutes and then were sprayed with Primuline solution and viewed under UV light (32, 33) . The neutral glycosphingolipid spots were identified and scraped off. The neutral glycosphingolipid spots scraped from the chromatoplates of both A-and B-subfractions were divided into four fractions according to their glycosphingolipid composition: I) ceramide, 2) monoglycosylceramide to triglycosylceramide, 3) tetraglycosylceramide, and 4) pentaglycosylceramide to the origin.
Fractions 1 and 2 from the B-subfraction were discarded because no glycosphingolipids were present. Fraction 3 from both the A-and B-subfractions and fraction 4 from both the A-and B-subfractions were combined. The neutral glycosphingolipids were eluted from all these fractions: A-I, A-2, combined A-3 and B-3, and combined A-4 and B-4. The elutions were performed with the following solvents: chloroform: methanol, I: I (vollvol); chloroform.methanol, 1:2 (vol/ vol); chloroform:methanol, 1:4 (vollvol); and methanol. The eluates were concentrated and treated differently as described below. Fraction A-I was ready for quantitative determination of ceramide by analytic thin-layer chromatography without the need for dry columns. Fraction A-2 and the combined fraction A-3-B-3 were subjected to further purification by chromatography on small dry columns. We prepared these columns by packing 2-ml Pasteur pipettes with 200 mg dry silicic acid followed by 500 mg of a dry mixture of silicic acid:magnesium silicate (Florisil), 1:1 (wt/wt). The columns were activated at 175°C overnight and cooled in a desiccator immediately prior to sample application. The samples were eluted with a mixture of pyridine:acetone:chloroform:water, 60:40:5:4 (voll vol). With fraction A-2, 1.5 ml of eluate was collected, evaporated to dryness, and redissolved in a small volume of chloroform:methanol, 1:1 (vollvol). This eluate contained monoglycosylceramide, diglycosylceramide, triglycosylceramide, and sulfa tide and was free from phospholipid contamination. It was ready for quantitative glycosphingolipid determination by analytic thin-layer chromatography. When the same procedure was applied to the combined fraction A-3-B-3, 7 ml of eluate was collected. The eluate was free from phospholipid contamination and could be used for quantitative determination of tetraglycosylceramide by analytic thin-layer chromatography.
The combined fraction A-4-B-4 eluate from preparative thin-layer chromatography was concentrated to a small volume and applied to another thin-layer chromatogram, which was developed in a mixture of chloroform:methanol:2 N aqueous NH40H, 60:35:8 (vol/vol). The chromatogram was sprayed with Primuline, and the areas occupied by hematoside, monosialoganglioside, pentaglycosylceramide, and hexaglycosylceramide were scraped off. The glycosphingolipids were eluted in the same way as from preparative thin-layer chromatograms (see above). Ganglioside fractions were quantitated by determination of their sialic acid content as described in "Determination of gangliosides in upper Folch phase."
The quantities of neutral glycosphingolipid were determined densitometrically by analytic thin-layer chromatography. Chromatograms for ceramide were developed with hexane:chloroform:acetone:acetic acid, 20:70:20:2 (vol/vol). For all other neutral glycosphingolipids, chromatograms were developed with chloroform:methanol:water, 60:30:6.5 (vol/vol) or chloroform: methanol:2.5 N aqueous NH40H, 60:35:8 (vol/vol). After development, the chromatograms were sprayed with dichromate-sulfuric acid reagent [a saturated solution of K2Cr207 in 70% (vol/vol) aqueous sulfuric acid] and then heated in an oven for 25-30 minutes at 180" C. As a rule, a lO-mg equivalent of fraction 1 was applied for densitometric measurements; a 20-mg equivalent of fraction 2, a 40-mg equivalent of fraction 3, and a 100-mg equivalent of fraction 4 were used. Along with the fractions, reference standards were chromatographed in the appropriate amounts.
RESULTS
In table 1 are shown the ganglioside profiles of the nontreated, nonmetastatic tumor HS #1 and of the nontreated, highly metastatic tumor HEp 3. The results are expressed in nanomoles per 100 mg lipids extracted. The total amount of lipid-bound sialic acid was almost 2.5-fold higher in HS #1 than in HEp #3. This difference was mainly due to the higher content of monosialoganglioside (GMl and GM2) and disialoganglioside in HS #1 (3.7-and 3.8-fold, respectively). The content of hematoside in HS #1 was also higher than in HEp #3. The content of trisialoganglioside was approximately the same in both untreated tumors. A projection of the values for the content of these gangliosides per gram of fresh tumor tissue only slightly decreased the differences between these 2 tumors.
The differences in the ganglioside quantities and patterns of HS #1 and HEp #3 could be simply a reflection of differences in the original ganglioside patterns of the progenitor tissues of these 2 tumors, or they could be related to differences in their metastatic abilities or a combination of both. To elucidate whether a relationship exists between ganglioside patterns and/or quantities and the process of metastasis formation, HEp #3 and HS #1 were treated with 6,7,8,9-tetrahydro-l-mercapto-l ,2,4-triazolo-[ 4,3 -a]quinazolin-5-01. This compound, at a dose level of 2.5 mg/egg, completely inhibited the formation of metastasis in HEp #3. It had no effect on the ganglioside level or profile of HS #1 (table 1; T /e) with the possible exception of the trisialoganglioside whose content slightly increased. However, treatment of HEp #3 substantially increased (63%) the total content of lipidbound sialic acid. This was due to increases in the content of hernatoside, monosialoganglioside, and disialoganglioside as shown in table 1 (HEp #3, treated column, and T /e) that occurred almost to the same degree for all these three species of gangliosides. The effect of the compound tested on trisialoganglioside in HEp #3 was similar to that in HS #1. Thus the biologic change observed in HEp #3 from a metastasizing to a nonmetastasizing tumor after treatment with the quinazolinol derivative coincided with the alteration of ganglioside levels, increasing the content of hernatoside, monosialoganglioside, and disialoganglioside. In other words, the differences in the total content of gangliosides of treated HEp #3 and nontreated HS #1 were smaller than between nontreated HEp #3 and nontreated HS #1. However, no substan- tial selective relative increase of any species of gangliosides was noted in HEp #3 after treatment.
In table 2, the neutral glycosphingolipid composition of nontreated and treated HS #1 and nontreated and treated HEp #3 tumors is shown. The difference in neutral glycosphingolipid composition between control HS #1 and control HEp #3 was much less pronounced than for gangliosides. HEp #3 contained somewhat less ceramide and monoglycosylceramide but more diglycosylceramide and tetraglycosylceramide. However, the total amount of neutral glycosphingolipids in nanomoles per 100 mg of lipid extracted was the same in both tumors. The treatment of HS #1 tumors with 6,7,8,9-tetrahydro-l-mercapto-l,2,3-triazolo-[4,3-a]quinazoliri-fi-ol did not demonstrably affect the neutral glycosphingolipid content of HS #1 but altered it in HEp #3 by decreasing the content of all neutral glycosphingolipids. The content of diglycosylceramide and tetraglycosylceramide was especially decreased.
We have mentioned that 6,7,8,9-tetrahydro-l-mercapto-I ,2,4-triazolo-[4,3-a [quinazolin-fi-ol (at a dose level of 2.5 mg/egg used in the above described experiments) not only completely inhibited the formation of metastasis but also inhibited to a certain extent growth of the primary tumors (see "Materials and Methods," "Compounds tested"). However, this compound at a smaller dose of 1.25 mg/egg still inhibited the formation of metastasis (on the average of 88%) but had no effect on the growth of the primary tumor. Therefore, to eliminate the possible effect of a growth rate change in the primary tumor on the glycosphingolipid pattern, two experiments were performed with the use of only 1.25 mg of the quinazolinol derivative per egg. Table 3 shows the results of these experiments. The total amount of lipid-bound sialic acid increased by 39%. Among individual ganglioside classes, the highest increase was observed in disialoganglioside values, whereas the values for hematoside and monosialoganglioside were substantially lower than when the 'higher dose of the quinazolinol derivatives was used. An exact evaluation of these results presents difficulties because of two biologic variables: the difference in the growth rate of primary tumors and the difference in the degree of inhibition of metastasis formation. However, whether the growth of the primary tumor was affected or not, the inhibition of metastasis formation was concomitant with the increase in the amount of gangliosides in cells of primary tumors. In HS #1, 2.5 mg quinazolinol derivative/egg did not cause an alteration of the glycosphingolipid pattern in spite of the fact that this compound caused some inhibition in the growth rate of the primary tumor.
The relationship between the inhibition of metastasis formation and the alteration of the ganglioside pattern in the primary HEp #3 tumor has also been demonstrated with another compound. When 2.5-diphenylthiazolo- [5,4-d] thiazole was injected at a dose of 500 p.g/egg, the formation of metastasis in HEp #3 tumors was prevented (Gitterman CO: Manuscript in preparation). At the same time, it also changed the amount of gangliosides in HEp #3 tumors. In table 4, the ratio of the content of different ganglioside classes between thiazole derivative-treated tumors and nontreated tumors per 100 mg lipids extracted is shown. The highest ratio was observed for disialoganglioside. Substantial increases also existed in the content of monosialoganglioside and hematoside. The treatment did not affect the content of trisialoganglioside. Treatment of HEp #3 with the thiazole derivative also caused an increase in the growth rate of primary tumors. The experimental conversion of extensively metastasizing HEp #3 to nonmetastasizing tumor by treatment with two different chemical compounds correlates with an increase in ganglioside content of these tumors. These observations, to a certain extent, confirm the results obtained by the Keenan research team from Purdue University (35, 36) . These authors observed that transplantable hepatomas (originally induced by N-2-fluorenylacetamide), designated T-l and T-2, and which apparently did not metastasize, had a higher content of gangliosides than did hepatoma T-3, which did metastasize. As a working 'hypothesis rather than established fact, correlation between the level of gangliosides and metastasis formation may be interpreted as indicating that ganglioside levels on the cell surface determine cell adhesiveness and, therefore, the formation of metastasis.
Our experiments with HS #1 and HEp #3 tumors were performed on their whole cell lipid extracts. Glycosphingolipids, and especially gangliosides, although present in all subcellular fractions, are found in higher concentrations in the plasma membranes isolated from normal and malignant cells, as has been demonstrated in our laboratory (37, 38) and other laboratories (39) (40) (41) (42) . Therefore, the results obtained by us for HS #1 and HEp #3 most likely reflect particularly the alteration of gangliosides in the plasma membranes of cells in these 2 tumors. Roseman and other investigators (9) (10) (11) (12) (13) (14) (15) demonstrated that glycoconjugates under certain conditions may play an important role in cell adhesion. As mentioned earlier, formation of metastasis is a very complex process, and most likely the degree of cell adhesion is one of the many factors that determine whether the malignant tumor will or will not metastasize. Apparently, cell adhesion may have a crucial role in two areas: a) in the primary tumor where it may determine the degree of ease with which malignant cells dissociate from the primary tumor mass to become blood-borne cells or clumps of cells, and b) in the target organ. Here the interaction between blood-borne malignant cells and vascular endothelial cells may determine whether an incipient metastatic site is established. Our results show that an increase in the ganglioside content of certain types of tumor cells (and most likely on their cell surfaces) coincides with a decrease or complete elimination of metastasis formation. Theoretically, this shown to have a cell surface-exposed ganglioside content (hematoside) that was 45-56% higher than cell line Fl. The cell surface-exposed diglycosylceramide and sialylglycoprotein contents are also higher in cell line FlO than in Fl. However, the implantation of FI and FlO cells was studied in normal mice by the abovementioned authors, whereas under natural (nonexperimental) conditions, implantation of blood-borne malignant cells occurs in tumor-bearing animals in which other factors (e.g., host defense mechanisms) may also play an important role. Contradiction between our results and the observations of Yogeeswaren et al. (43) concerning the role of the level of gangliosides in metastasis formation may be more apparent than real. If we assume that malignant cell adhesion in a primary tumor is determined by cell surface gangliosides, then a high level of gangliosides in the primary tumor should decrease the number of tumor cells able to break loose and enter the lymphatic or circulatory systems with possible metastasis formation. However, blood-borne malignant cells or tumor cell clumps that are either detached from the primary tumor or injected experimentally and have a higher ganglioside content have a greater chance of adhesion to endothelial cells with secondary tumor formation. The balance of these two tendencies will possibly determine the occurrence and extent of metastasis formation. However, at present this hypothesis is only a working one. In addition to cell adhesion, several other factors may determine the spread of cancer.
Practically all malignant tumors grown in situ are characterized by a substantial alteration of their glycosphingolipid patterns as compared with the progenitor tissues (44) (45) (46) (47) . Therefore, a logical question is: Do tumor glycosphingolipid profiles always show correlation with metastatic behavior of tumors? Our preliminary data (unpublished results) obtained on Lewis lung tumors may, to a degree, answer this question. Salsbury and colleagues (48) (49) (50) demonstrated that metastasis of Lewis lung carcinoma can be inhibited completely by a certain amount of (±)-1,2~bis(3,5-di oxopiperazin-l-yl)propane without affecting the growth rate of the primary implant. These authors concluded that metastatic formation was arrested due to profound vascular changes ("normalization") in the primary tumor. This normalization probably substantially decreased the number of malignant cells entering the circulatory system.
Ganglioside analysis conducted in our laboratory on lipids extracted from nontreated and treated Lewis lung carcinoma did not reveal an increase in the level of gangliosides for treated nonmetastatic tumors. In general, some decrease in the content of all ganglio-sides of treated nonmetastatic Lewis lung carcinoma was found. Therefore, apparently only in some types of malignant tumors can the formation of metastasis possibly be linked to glycosphingolipid metabolism.
